ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Seraphina Therapeutics has raised $5.5 million in a first funding round, led by Domain Associates, to advance dietary supplements and food fortifiers made from pentadecanoic acid, a trace odd-chain saturated fatty acid found in butter and some fish and plants. The California-based firm claims that the acid, also called C15:0, is potentially essential to cardiometabolic and liver health. C15:0 was discovered by Stephanie Venn-Watson, Seraphina’s CEO. The company plans to launch C15:0 supplements this fall.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter